The scientific article summarizes the implementation and results of the study.

• ·      Potential synergistic effect with Rituximab as VAL001 increases the levels of the surface protein CD20.
• ·      Overall Survival Analysis for 32 patients treated with VAL001 and R-CHOP shows that 1-year survival is 100% and 2-year survival is 96.8%. Comparative data from a matched reference population of 330 patients from The Swedish lymphoma registry treated with R-CHOP alone provides 1-year survival of 89.6% and 2-year survival of 81.7%. This shows a statistically assured survival benefit (p = 0.034) for patients treated with VAL001 and R-CHOP compared to those treated between 2000-2015 with R-CHOP alone.

Kristina Drott, inventor of VAL001 and author of the article says in a comment: "It is very honorable that the article was accepted after such a quick review which indicates great interest in our results." 

VAL001 is a patented, with patents granted in Europe and Japan, combination of approved and well-tolerated drugs, and is given as pre-treatment for cytostatic treatment (R-CHOP) in the treatment of diffuse large cell B cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma which annually affects about 60,000 people in the US and Europe. The 5-year survival rate for the disease is approximately 65-70%.

Phase I/IIa studies has been conducted at Skåne's oncology clinic, SUS in Lund / Malmö, Akademiska sjukhuset in Uppsala and at Cancer Center, Norrlands University Hospital in Umeå. VAL001 is given as pre-treatment for standard chemotherapy, with the addition of Rituximab (R-CHOP), in the treatment of diffuse large cell B-lymphoma.

This information is information that Respiratorius AB (Publ) is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on May 4, 2018.